Bevacizumab
- TRADE NAME: Avastin (Genentech)
- INDICATIONS: Colon cancer; lung cancer; glioblastoma; renal-cell carcinoma
- CLASS: Angiogenesis inhibitor / antiangiogenic agent, Biologic, Covid-19 putative drug, Monoclonal antibody
- HALF-LIFE: 20 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Antineoplastics, Irinotecan, Sorafenib, Sunitinib
PREGNANCY CATEGORY: C
Investigated for treating COVID-19.
GASTROINTESTINAL PERFORATIONS, SURGERY AND WOUND HEALING COMPLICATIONS, and HEMORRHAGE
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tabs (above) to see reviews of bevacizumab in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/19/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric